Genmab (GMAB) Announced Results From its EPCORE NHL-2 Trial

Genmab A/S (NASDAQ:GMAB) is one of the 10 Best Growth Stocks to Buy With Huge Upside Potential. On June 15, Genmab A/S (NASDAQ:GMAB) announced results from its EPCORE NHL-2 trial, Arm 10. The study tested Epcoritamab, which is a bispecific antibody, in combination with R-ICE chemotherapy.

The study was focused on adult patients with relapsed or refractory diffuse large B-cell lymphoma who could undergo autologous stem cell transplantation. The results revealed that the combination therapy achieved an overall response rate of 87%. Moreover, 65% of patients had a complete response where no signs of cancer remained. On the other hand, 23% had a partial response.

The treatment was regarded as generally well-tolerated, and the most common side effects were low white blood cells, anemia, and low platelets. These results are promising for high-risk patients who need new options. The combination may help more patients reach a stem cell transplant, which can be curative. However, this therapy is still investigational and not yet approved for this use.

Genmab A/S (NASDAQ:GMAB) is a biotechnology company based in Denmark that develops antibody-based therapies for cancer and other diseases.

While we acknowledge the potential of GMAB as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.